Synergistic Minimally Invasive Surgery and Deferoxamine in ICH

A phase 2/3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 240 participants.

Also called NCT07162363

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 2/3
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07162363
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07162363. Randomized; single masking; primary purpose treatment. Start 2026-03-01 (anticipated); primary completion 2028-12-30 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Synergistic Minimally Invasive Surgery and Deferoxamine in ICH
Acronym
SMAD
Condition
Intracerebral Hemorrhage
Condition
ICH - Intracerebral Hemorrhage
Intervention (Procedure)
Minimally Invasive surgery (MIS)
Intervention (Drug)
Deferoxamine
Intervention (Other)
Standard Medical Care (SMD)
Lead sponsor
University of Illinois Chicago (class: other)

Record details

Record id
cardio:ct-nct07162363
Content hash
9e10a92186a0e619c4328de7737f493dce70e2450f080e89b3012fa1317d3cbe